Try a new search

Format these results:

Searched for:



Total Results:


Increased Yield of Hereditary Cancer Risk Assessment in a GI Office Practice Utilizing NCCN Guidelines and Panel Testing [Meeting Abstract]

McKinley, Matthew; Deede, Jennifer; Rochester, Jeremy; Gal, Robert; Gerardi, Frank; Pathical, Betsy; Zaidi, Hina; Markowitz, Brian; Adler, Michael; Lih-Brody, Lisa
ISSN: 0002-9270
CID: 4848782

Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy

Izzy, Manhal; Jibara, Ghalib; Aljanabi, Aws; Alani, Mustafa; Giannattasio, Emily; Zaidi, Hina; Said, Zaid; Gaglio, Paul; Wolkoff, Allan; Reinus, John F
BACKGROUND:Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. AIMS/OBJECTIVE:To provide information about the limitations of medical treatment of hepatitis C in real-world patients. METHODS:We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. RESULTS:Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five- (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan-Meier analysis (80.3% vs. 74.5%, P = 0.005). CONCLUSION/CONCLUSIONS:Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.
PMID: 27493457
ISSN: 0973-6883
CID: 5007072

Risk of New or Recurrent Cancer in Patients with Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-TNF Agents

Axelrad, Jordan; Bernheim, Oren; Colombel, Jean-Frederic; Malerba, Stefano; Ananthakrishnan, Ashwin; Yajnik, Vijay; Hoffman, Gila; Agrawal, Manasi; Lukin, Dana; Desai, Amit; Mceachern, Elisa; Bosworth, Brian; Scherl, Ellen; Reyes, Andre; Zaidi, Hina; Mudireddy, Prashant; DiCaprio, David; Sultan, Keith; Korelitz, Burton; Wang, Erwin; Williams, Renee; Chen, LeaAnn; Katz, Seymour; Itzkowitz, Steven
BACKGROUND AND AIMS: Our understanding of malignancy associated with immunosuppression in patients with inflammatory bowel disease (IBD) comes from studies of individuals with no history of cancer. We investigated whether patients with IBD and a history of cancer who were subsequently immunosuppressed have an increased risk of developing incident cancer. METHODS: We performed a retrospective analysis of data from 333 patients with IBD treated at 7 academic medical centers who developed cancer and subsequently received treatment with anti-tumor necrosis factor (TNF), anti-TNF with an anti-metabolite (thiopurines, methotrexate), anti-metabolites, or no subsequent exposure to immunosuppressive agents (controls). We collected data on their primary outcomes of incident cancers (new or recurrent). Hazard ratios (HRs) were calculated using Cox proportional hazards and Kaplan-Meier survival curves; study groups were compared using the Log-Rank test. RESULTS: During the follow-up period, 90 patients (27%) developed an incident cancer. Patient characteristics between groups differed, but matching was not possible due to the relatively small sample sizes. There was no difference in time to (p=0.14) or type of (p= 0.61) incident cancer among the 4 groups. After adjusting for recurrence risk for type of prior cancer, there was no difference in risk of incident cancer (HR for anti-TNF=0.32; 95% confidence interval [CI], 0.09-1.09; HR for anti-TNF with an anti-metabolite=0.64; 95% CI, 0.26-1.59; HR for an anti-metabolite=1.08; 95% CI, 0.54-2.15) or time to subsequent cancer between study arms (p=.22). CONCLUSION: Based on a retrospective study, in patients with IBD and a history of cancer, exposure to an anti-TNF agent or an anti-metabolite following cancer was not associated with an increased risk of incident cancer, compared to patients who did not receive immunosuppression. Larger, matched, prospective studies are needed to confirm these findings.
PMID: 26247164
ISSN: 1542-7714
CID: 1709242

Successful Treatment of a Persistent Esophageal Lichen Planus Stricture With a Fully Covered Metal Stent [Case Report]

Stein, Peter; Brun, Alexander; Zaidi, Hina; Sejpal, Divyesh V; Trindade, Arvind J
We report a case of a 51-year-old woman with an esophageal lichen planus (ELP) stricture refractory to medical therapy and endoscopic stricture dilation. A multidisciplinary decision was made to place an esophageal fully covered metal stent. The stent was removed 6 weeks later and the patient is doing well on 3-month follow up. We show that a removable esophageal stent is an option after standard medical therapy and endoscopic dilations fail. This is the first reported use of an esophageal stent for therapy of an ELP stricture.
PMID: 26958558
ISSN: 2326-3253
CID: 5007062

Patients With Inflammatory Bowel Disease and a History of Cancer: The Risk of Cancer Following Exposure to Immunosuppression [Meeting Abstract]

Axelrad, Jordan E.; Bernheim, Oren; Colombel, Jean-Frederic; Malerba, Stefano; Ananthakrishnan, Ashwin N.; Yajnik, Vijay; Hoffman, Gila; Agrawal, Manasi; Lukin, Dana J.; Desai, Amit P.; McEachern, Elisa; Bosworth, Brian; Scherl, Ellen J.; Reyes, Andre; Zaidi, Hina; Mudireddy, Prashant R.; DiCaprio, David; Sultan, Keith; Korelitz, Burton I.; Wang, Erwin; Williams, Renee; Chen, Lea Ann; Katz, Seymour; Itzkowitz, Steven H.
ISSN: 0016-5085
CID: 3177942